PATHOGENETIC CORRECTION OF MICROVASCULAR DYSFUNCTION WITH THE USE OF IMMUNOMODULATING THERAPY IN PATIENTS WITH RESISTANT ANGINA

Resistance to standard antianginal therapy in patients with microvascular angina is primarily due to endothelial dysfunction and inflammatory changes in the microcirculation, necessitating the use of pathogenetically based immunomodulatory therapy. Scientific substantiation and clinical testing of this approach can improve the effectiveness of treatment for resistant forms of angina, improve patients' quality of life, and reduce the risk of cardiovascular complications.